{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:28Z","timestamp":1792787308573,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00346510"],"award-info":[{"award-number":["RS-2024-00346510"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Drug Development Fund","award":["RS-2022-DD124046"],"award-info":[{"award-number":["RS-2022-DD124046"]}],"id":[{"id":"https:\/\/ror.org\/01h8vbd96","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Korea Health Industry Development Institute","award":["RS-2024-00439838"],"award-info":[{"award-number":["RS-2024-00439838"]}],"id":[{"id":"https:\/\/ror.org\/00fdzyk40","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,16]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggressive clinical behavior. This study aimed to develop and characterize optimized L1CAM-targeted chimeric antigen receptor-T (CAR-T) cells with improved efficacy and safety, using patient-derived preclinical models of ovarian and gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>L1CAM expression was assessed in tumor tissues from patients with ovarian cancer (OC;n=227) and gastric cancer (GC;n=132), followed by an analysis of its clinical impact. A panel of L1CAM-targeted CAR constructs incorporating distinct hinge and co-stimulatory domains was systematically evaluated. Functional activity was assessed by cytotoxicity and cytokine release assays using cancer cell lines and patient-derived tumor cells. Antitumor efficacy, persistence, and safety were evaluated in xenograft and patient-derived xenograft (PDX) models, including NanoLuc-based in vivo tracking of CAR-T cell distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High L1CAM expression correlated with aggressive clinicopathological features and adverse prognosis in patients with OC. Among the constructs tested, CAR-T cells incorporating an IgD\/IgG1 hybrid hinge and dual CD28-ICOS co-stimulatory domains demonstrated the most potent antigen-specific activity. These cells exhibited enhanced cytotoxicity, robust interferon-\u03b3 production, and sustained functional activity. In vivo, optimized L1CAM CAR-T cells achieved complete tumor regression in OC PDX models and significant tumor suppression in GC models, with durable tumor control and CAR-T persistence. Intraperitoneal delivery further improved therapeutic efficacy and CAR-T cell localization compared with intravenous administration. Importantly, no evidence of neurotoxicity or systemic toxicity was observed, supporting a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Optimized L1CAM-targeted CAR-T cells demonstrate potent, durable, and antigen-specific antitumor activity with a favorable safety profile in preclinical models of OC and GC. The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014131","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:20:16Z","timestamp":1789737616000},"page":"e014131","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8834-8919","authenticated-orcid":false,"given":"Xiumei","family":"Che","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-7462","authenticated-orcid":false,"given":"Un-Jung","family":"Yun","sequence":"additional","affiliation":[{"name":"Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-6851","authenticated-orcid":false,"given":"Junsub","family":"Lee","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-3564","authenticated-orcid":false,"given":"Hyun-Hee","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4156-2665","authenticated-orcid":false,"given":"Ju-Yeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-660X","authenticated-orcid":false,"given":"Jungmin","family":"Jeon","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2836-6450","authenticated-orcid":false,"given":"Subin","family":"So","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-3043","authenticated-orcid":false,"given":"Youngyoub","family":"Kim","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2840-9410","authenticated-orcid":false,"given":"Jin-A","family":"Chae","sequence":"additional","affiliation":[{"name":"Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-5969","authenticated-orcid":false,"given":"Xianglan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yanbian University Hospital, Yanji, Jilin, China"},{"name":"Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9585-4968","authenticated-orcid":false,"given":"Hyoyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0385-6151","authenticated-orcid":false,"given":"Jiwoo","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-5054","authenticated-orcid":false,"given":"Eunhyang","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-3560","authenticated-orcid":false,"given":"Eun Ji","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9167-8682","authenticated-orcid":false,"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-3387","authenticated-orcid":false,"given":"Minkyu","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"},{"name":"Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091806201001000_14.9.e014131.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026091806201001000_14.9.e014131.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026091806201001000_14.9.e014131.3","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2026091806201001000_14.9.e014131.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"2026091806201001000_14.9.e014131.5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2026091806201001000_14.9.e014131.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2"},{"key":"2026091806201001000_14.9.e014131.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026091806201001000_14.9.e014131.8","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026091806201001000_14.9.e014131.9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32552-2"},{"key":"2026091806201001000_14.9.e014131.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"2026091806201001000_14.9.e014131.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2026091806201001000_14.9.e014131.12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4143\/crt.2024.1222","article-title":"The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine","volume":"57","author":"Yun","year":"2025","journal-title":"Cancer Res Treat"},{"key":"2026091806201001000_14.9.e014131.13","doi-asserted-by":"publisher","DOI":"10.1038\/334701a0"},{"key":"2026091806201001000_14.9.e014131.14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr568"},{"key":"2026091806201001000_14.9.e014131.15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-6-43","article-title":"L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer","volume":"6","author":"Chen","year":"2013","journal-title":"J Hematol Oncol"},{"key":"2026091806201001000_14.9.e014131.16","doi-asserted-by":"crossref","DOI":"10.1038\/srep37652","article-title":"TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling","volume":"6","author":"Roberts","year":"2016","journal-title":"Sci Rep"},{"key":"2026091806201001000_14.9.e014131.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010217","article-title":"L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population","volume":"12","author":"Terraneo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026091806201001000_14.9.e014131.18","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02117-z"},{"key":"2026091806201001000_14.9.e014131.19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/PAS.0000000000002027","article-title":"L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression","volume":"47","author":"Wiedenhoefer","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"2026091806201001000_14.9.e014131.20","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.143.7.2067"},{"key":"2026091806201001000_14.9.e014131.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61873-4"},{"key":"2026091806201001000_14.9.e014131.22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41374-019-0366-y","article-title":"Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry","volume":"100","author":"Haragan","year":"2020","journal-title":"Lab Invest"},{"key":"2026091806201001000_14.9.e014131.23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026091806201001000_14.9.e014131.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.281"},{"key":"2026091806201001000_14.9.e014131.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026091806201001000_14.9.e014131.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56356-4"},{"key":"2026091806201001000_14.9.e014131.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123743","article-title":"Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026091806201001000_14.9.e014131.28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051327","article-title":"Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models","volume":"12","author":"Garcia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026091806201001000_14.9.e014131.29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"2026091806201001000_14.9.e014131.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:20:19Z","timestamp":1789737619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2025-014131"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014131","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}